Liquidia Technologies Inc (LQDA)
NASDAQ:LQDA
L606 Inhalation Suspension
Pulmonary Arterial Hypertension, Pulmonary Hypertension Due To Lung Diseases
Phase III
Active Not Recruiting
A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD
Dec 21, 2020
―
Liq861 Inhaled Treprostinil
Primary Pulmonary Hypertension
Phase III
Active Not Recruiting
Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil
Jun 05, 2019
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Liquidia Technologies Inc (LQDA) have in its pipeline
LQDA is currently developing the following drugs: L606, L606 Inhalation Suspension, Liq861 Inhaled Treprostinil. These drug candidates are in various stages of clinical development as the company works toward FDA approval.